Erica Jordan - 16 Apr 2024 Form 4 Insider Report for Revance Therapeutics, Inc.

Role: Chief Commercial Officer
Signature: /s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 16 Apr 2024
Net transactions value: -$9,096
Form type: 4
Filing time: 17 Apr 2024, 16:34:50 UTC
Previous filing: 29 Feb 2024
Next filing: 06 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVNC	Common Stock	Sale	$9,096	-2,392	-2%	$3.80	114,864	16 Apr 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares required to be sold by the Reporting Person, to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") granted on April 3, 2023 which vest in equal installments over a four year period. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2	The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Content

Represents the number of shares required to be sold by the Reporting Person, to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") granted on April 3, 2023 which vest in equal installments over a four year period. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.